Canadian
Bio Med Systems, Inc., enters billion dollar market
with two new Ophthalmic drugs.
New York, Montreal,
San Diego California , February 11, 2009 – Canadian
Bio Med Systems Inc., a subsidiary of ICBS Ltd., (OTCPK:
ICBT),) , and Ocular Therapeutics Inc. of San Diego
California, announced that it has acquired the licensing
rights to two new potentially revolutionary drugs
in the billion dollar ophthalmic arena .
The drug for the treatment of glaucoma is being
developed by Daniel Stamer, PhD and Ronald Heimark,
PhD at the University of Arizona. Glaucoma is a prevalent
eye disease is one of the leading causes of blindness
in the world. Patient compliance is a serious problem
in glaucoma because of the frequency which conventional
medication is required. The new drug being developed
may change the paradigm of glaucoma therapy.
Eugene Levin, PhD at Torrey Pines in San Diego, California
is developing the new drug for age-related macular
degeneration (AMD). The protein in this compound is
derived from a larger, naturally occurring human protein
which will be used to control dangerous vessel growth
in the retina at the very back of the eye. The new
drug being developed is a much smaller protein than
other AMD drugs being used today which means it may
be used less frequently.
“We are very pleased that we have this agreement
with Canadian Bio Med Systems, Inc. since it will
allow for the development of these two very important
products in two very important and sizable markets.”
Said Richard H. Keates, MD, Chairman of Ocular Therapeutics,
Inc. “The products being developed could make
a considerable difference in the treatment of two
of the most serious ophthalmic condition today.
Additional joint research is expected to commence
in Canada under the direction of Dr. George Tsoukas
of McGill University.
SOURCE: Ocular Therapeutics Inc.
CONTACT : Randy Bailey
TELEPHONE: 949- 228-4258
SOURCE: ICBS Limited www.icbs.ca
back to top
Canadian
Bio Med Systems Inc., Initiates Scientific Panel
NEW YORK, MONTREAL,
SAN DIEGO, July 28 2009 /PRNewswire-FirstCall/
- Canadian Bio Med Systems Inc., a subsidiary of ICBS
Ltd., (OTCPK: ICBT),) , and Ocular Therapeutics Inc.,
of San Diego California, announced today that Dr Jeffrey
L. Olson, M.D. has joined the scientific panel of
Canadian Bio Med Systems Inc.
Dr. Jeffrey Olson
of the
University of
Colorado , a retinal
surgeon, has become a member of (CBMS's) scientific
board.
Dr. Olson is a member
of the
American
Academy of Ophthalmology
, the Association for Research in Vision and Ophthalmology
and The American Society of Retinal Specialists. Dr.
Olson has published numerous scientific papers and
has been awarded grants from the National Institute
of Health . Dr. Olson has participated in both pre-clinical
and clinical studies for important retinal compounds.
Commenting on the
Clinical Panel member, Dr. Richard H. Keates, Chairman
of Ocular Therapeutics (CBMS), says "Dr. Olson
is the perfect person to help direct our efforts in
solving the problems of Age-related Macular degeneration.
His experience with other projects such as this can
help avoid pitfalls and speed this product to market
successfully."
Age-Related Macular
Degeneration (AMD) is the leading cause of blindness,
worldwide, for people over 55 years of age. The incidence
of AMD in persons aged 55 is 1% and increases to 15%
for persons aged 80. This debilitating disease has
proven to be difficult to treat and only a very few
drugs have been developed which have positive effects.
The drug under development
by Canadian Bio Med Systems , has a very different
mode of action than the current therapeutic products.
It can be used alone or in conjunction with these
currently available products.
The product under
development by CBMS, LD22-4 has the advantage of being
a very small molecule meaning that fewer treatments
will be needed compared to current therapies, This
will help reduce the pain and frequency of injection
to the patient and potentially the cost of the treatment.
Canadian Bio Med
is developing the new product in
Montreal in conjunction with its partner,
Ocular Therapeutics Inc. of
San Diego , California
. The drug is moving toward human clinical
trials in Canada
and the
United States next
year.
The market for products
treating AMD has been estimated at over $750 million
annually and growing at a rate of over 10% yearly
as the population ages.
NB. This news release
includes statements that constitute forward-looking
statements. Please be aware that any such forward-looking
statements are not guarantees of future performance
and involve significant risks and uncertainties, and
that actual results may vary materially from those
in the forward-looking statements as a result of any
number of factors, including the risk factors contained
in the Company's disclosure documents. back
to top
Major
Firms Eyeing CBMS Development of New Glaucoma Treatment
New
York, Montreal, San Diego California , July
7, 2009– Canadian
Bio Med Systems Inc., a subsidiary of ICBS Ltd., (OTCPK:
ICBT),)
, and Ocular Therapeutics Inc. of San Diego California,
announced that Ocular Therapeutics has signed
non-disclosure agreements with two of the largest
pharmaceutical firms in the world.
These unnamed companies are interested in a
new treatment approach in the largest of the ophthalmic
markets.
High
Interest in a New Approach to Glaucoma Treatment
One
of the reasons these large entities are so interested
in this project is because of a
recent article in the “Review of Ophthalmology”
supports the development of a new class of glaucoma
drugs now being tested by Canadian Bio Med Systems,
Inc. (CBMS). The article was identified incorrectly
as being from the “Survey of Ophthalmology” in an
earlier release. The article entitled “Glaucoma Drugs:
The Search for New Options” quotes David Epstein,
MD, Chairman of Ophthalmology at Duke University School
of Medicine in
Durham North Carolina . Dr. Epstein points out that
the approach of improving aqueous outflow in the eye
is “the most logical approach to treating glaucoma”
Glaucoma is caused
by an increase of intraocular pressure within the
eye. The new compound being developed by CBMS in conjunction
with Ocular Therapeutics, Inc. of
California
, specifically targets a portion of the eye, Schlemm’s
Canal, which is critical in achieving aqueous outflow
and lowering intraocular pressure.
This novel approach to treatment may require
application of the drug every three months, or even
less often, rather that twice per day. It could revolutionize
the treatment for glaucoma.
Dr. Epstein points
out the commercial aspects of such a potential drug
that improves aqueous outflow by saying that when
such a drug is developed “you will see every major
pharmaceutical company jump on the bandwagon and want
to have an outflow drug”. Further he says, “Then in
retrospect, every one will say ‘Why didn’t we work
on this drug sooner’”.
CBMS is completing
the studies required to enter into human clinical
trials in centers both in the
United States and
Canada
.
The
drug for the treatment of glaucoma is being developed
by Daniel Stamer, PhD and Ronald Heimark, PhD at the
University of Arizona . Glaucoma is a prevalent eye
disease is one of the leading causes of blindness
in the world. Patient compliance is a serious problem
in glaucoma because
of the frequency which conventional medication
is required. The new drug being developed may change
the paradigm of glaucoma therapy.
back to top
Canadian
Bio Med Attacks World’s Leading Cause of Blindness
New
York, Montreal, San Diego California , June
30,2009
– Canadian Bio Med Systems Inc., a subsidiary of ICBS
Ltd., (OTCPK:
ICBT),)
, and Ocular Therapeutics Inc. of San Diego California,
announced
the development of a
new AMD drug now being tested by Canadian Bio Med
Systems, Inc. (CBMS).
Age-Related Macular
Degeneration (AMD) is the leading cause of blindness,
worldwide, for people over 55 years of age. The incidence
of AMD in persons aged 55 is 1% and increases to 15%
for persons aged 80. This debilitating disease has
proven to be difficult to treat and only a very few
drugs have been developed which have positive effects.
The drug under development
by Canadian Bio Med Systems ,
has a very different mode of action than the
current therapeutic products. It can be used alone
or in conjunction with these currently available products.
The product under
development by CBMS, LD22-4 has the advantage of being
a very small molecule meaning that fewer treatments
will be needed compared to current therapies, This
will help reduce the pain and frequency of injection
to the patient and potentially the cost of the treatment.
Canadian Bio Med
is developing the new product in
Quebec in conjunction with its partner,
Ocular Therapeutics Inc. of
San Diego , California
.
The drug is moving toward human clinical trials
in Canada
and the United States
next year.
The
market for products treating AMD has been estimated
at over $750 million annually and growing at a rate
of over 10% yearly as the population ages.
back to top
Journal
Supports New
Ophthalmic Drug being developed by Canadian
Bio Med Systems , Inc.
New
York, Montreal, San Diego California , May
13, 2009
– Canadian Bio Med Systems Inc., a subsidiary of ICBS
Ltd., (OTCPK:
ICBT),)
, and Ocular Therapeutics Inc. of San Diego California,
announced
that a
recent article in the “Survey of Ophthalmology” supports
the development of glaucoma drugs now being tested
by Canadian Bio Med Systems, Inc. (CBMS). Journal
Supports CBMS’s New Drug
The article entitled
“Glaucoma Drugs: The Search for New Options” quotes
David Epstein, MD, Chairman of Ophthalmology at Duke
University School of Medicine in
Durham
North Carolina . Dr. Epstein
points out that the approach of improving aqueous
outflow in the eye is “the most logical approach to
treating glaucoma”
Glaucoma
is caused by an increase of intraocular pressure within
the eye. The new compound being developed by CBMS
in conjunction with Ocular Therapeutics, Inc. of
California
, specifically targets a portion of the eye, Schlemm’s
Canal, which is critical in achieving aqueous outflow
and lowering intraocular pressure.
This novel approach to treatment may require
application of the drug every three month rather that
twice per day. It could revolutionize the treatment
for glaucoma.
Dr.
Epstein points out the commercial aspects of such
a potential drug that improves aqueous outflow by
saying that when such a drug is developed “you will
see every major pharmaceutical company jump on the
bandwagon and want to have an outflow drug”. Further
he says, “Then in retrospect, every one will say ‘Why
didn’t we work on this drug sooner’”.
CBMS
is completing the studies required to enter into human
clinical trials in centers both in the
United States and
Canada
.
The
drug for the treatment of glaucoma is being developed
by Daniel Stamer, PhD and Ronald Heimark, PhD at the
University
of Arizona
. Glaucoma is a prevalent eye disease
is one of the leading causes of blindness in the world.
Patient compliance is a serious problem in glaucoma
because of
the frequency which conventional medication is required.
The new drug being developed may change the paradigm
of glaucoma therapy.
back to top
|
